• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腺相关病毒基因治疗泰萨氏症绵羊模型。

Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay-Sachs Disease.

机构信息

1 Scott-Ritchey Research Center, College of Veterinary Medicine, Auburn University, Auburn, Alabama.

2 Department of Neurology and Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts.

出版信息

Hum Gene Ther. 2018 Mar;29(3):312-326. doi: 10.1089/hum.2017.163. Epub 2017 Sep 18.

DOI:10.1089/hum.2017.163
PMID:28922945
Abstract

Tay-Sachs disease (TSD) is a fatal neurodegenerative disorder caused by a deficiency of the enzyme hexosaminidase A (HexA). TSD also occurs in sheep, the only experimental model of TSD that has clinical signs of disease. The natural history of sheep TSD was characterized using serial neurological evaluations, 7 Tesla magnetic resonance imaging, echocardiograms, electrodiagnostics, and cerebrospinal fluid biomarkers. Intracranial gene therapy was also tested using AAVrh8 monocistronic vectors encoding the α-subunit of Hex (TSD α) or a mixture of two vectors encoding both the α and β subunits separately (TSD α + β) injected at high (1.3 × 10 vector genomes) or low (4.2 × 10 vector genomes) dose. Delay of symptom onset and/or reduction of acquired symptoms were noted in all adeno-associated virus-treated sheep. Postmortem evaluation showed superior HexA and vector genome distribution in the brain of TSD α + β sheep compared to TSD α sheep, but spinal cord distribution was low in all groups. Isozyme analysis showed superior HexA formation after treatment with both vectors (TSD α + β), and ganglioside clearance was most widespread in the TSD α + β high-dose sheep. Microglial activation and proliferation in TSD sheep-most prominent in the cerebrum-were attenuated after gene therapy. This report demonstrates therapeutic efficacy for TSD in the sheep brain, which is on the same order of magnitude as a child's brain.

摘要

泰萨二氏病(TSD)是一种致命的神经退行性疾病,由己糖胺酶 A(HexA)缺乏引起。TSD 也发生在绵羊中,这是唯一具有疾病临床症状的 TSD 实验模型。使用连续的神经学评估、7 特斯拉磁共振成像、超声心动图、电诊断和脑脊液生物标志物来描述绵羊 TSD 的自然病史。还使用 AAVrh8 单顺反子载体对颅内基因治疗进行了测试,这些载体编码 Hex 的 α 亚基(TSD α)或分别编码 α 和 β 亚基的两种载体的混合物(TSD α + β),以高(1.3×10 载体基因组)或低(4.2×10 载体基因组)剂量注射。在所有接受腺相关病毒治疗的绵羊中,都观察到症状发作的延迟和/或获得性症状的减少。尸检评估显示,与 TSD α 绵羊相比,TSD α + β 绵羊的大脑中 HexA 和载体基因组分布更好,但所有组的脊髓分布都很低。同工酶分析表明,两种载体(TSD α + β)治疗后的 HexA 形成更好,高剂量 TSD α + β 绵羊的神经节苷脂清除最广泛。基因治疗后,TSD 绵羊的小胶质细胞激活和增殖(在大脑中最为明显)减弱。本报告证明了 TSD 在绵羊大脑中的治疗效果,其与儿童大脑的效果相当。

相似文献

1
Adeno-Associated Virus Gene Therapy in a Sheep Model of Tay-Sachs Disease.腺相关病毒基因治疗泰萨氏症绵羊模型。
Hum Gene Ther. 2018 Mar;29(3):312-326. doi: 10.1089/hum.2017.163. Epub 2017 Sep 18.
2
Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.新型载体设计与己糖胺酶变体助力自互补腺相关病毒治疗泰-萨克斯病
Hum Gene Ther. 2016 Jul;27(7):509-21. doi: 10.1089/hum.2016.013.
3
Investigating Immune Responses to the scAAV9- Gene Therapy Treatment in Tay-Sachs Disease and Sandhoff Disease Mouse Models.研究 scAAV9- 基因治疗在泰萨氏症和桑德霍夫病小鼠模型中的免疫反应。
Int J Mol Sci. 2021 Jun 23;22(13):6751. doi: 10.3390/ijms22136751.
4
AAV gene therapy for Tay-Sachs disease.腺相关病毒基因治疗泰萨二氏病。
Nat Med. 2022 Feb;28(2):251-259. doi: 10.1038/s41591-021-01664-4. Epub 2022 Feb 10.
5
[Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].[GM2神经节苷脂贮积症的分子发病机制与治疗方法]
Yakugaku Zasshi. 2013;133(2):269-74. doi: 10.1248/yakushi.12-00199.
6
Natural history of Tay-Sachs disease in sheep.绵羊泰萨氏症的自然史。
Mol Genet Metab. 2021 Sep-Oct;134(1-2):164-174. doi: 10.1016/j.ymgme.2021.08.009. Epub 2021 Aug 21.
7
Disorders病症
8
Three novel mutations in Iranian patients with Tay-Sachs disease.伊朗泰-萨克斯病患者中的三种新突变
Iran Biomed J. 2014;18(2):114-9. doi: 10.6091/ibj.1137.2013.
9
Spontaneous appearance of Tay-Sachs disease in an animal model.泰-萨克斯病在动物模型中的自发出现。
Mol Genet Metab. 2008 Sep-Oct;95(1-2):59-65. doi: 10.1016/j.ymgme.2008.06.010. Epub 2008 Aug 9.
10
Prenatal Diagnosis of Tay-Sachs Disease.泰-萨克斯病的产前诊断
Methods Mol Biol. 2019;1885:233-250. doi: 10.1007/978-1-4939-8889-1_16.

引用本文的文献

1
Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial.用于GM2神经节苷脂沉积症的双载体rAAVrh8基因疗法:一项1/2期试验
Nat Med. 2025 Aug 15. doi: 10.1038/s41591-025-03822-4.
2
Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease.泰-萨克斯病的诊断进展、病理机制、临床影响及未来治疗前景
Neurol Int. 2025 Jun 25;17(7):98. doi: 10.3390/neurolint17070098.
3
Magnetic Resonance Imaging as a Readout of CLN5 Gene Therapy Efficacy in Sheep.磁共振成像作为绵羊CLN5基因治疗疗效的一种读出方式
Brain Behav. 2025 Apr;15(4):e70431. doi: 10.1002/brb3.70431.
4
Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse model.向脑室内注射改良的己糖胺酶可改善GM2小鼠模型中的晚期神经退行性变。
PLoS One. 2025 Jan 3;20(1):e0315005. doi: 10.1371/journal.pone.0315005. eCollection 2025.
5
Intravenous gene therapy improves lifespan and clinical outcomes in feline Sandhoff Disease.静脉内基因疗法可改善猫类桑德霍夫病的寿命和临床结局。
bioRxiv. 2024 Nov 18:2024.11.15.623838. doi: 10.1101/2024.11.15.623838.
6
The prototypical interferonopathy: Aicardi-Goutières syndrome from bedside to bench.典型的干扰素病:从床边到实验室的 Aicardi-Goutières 综合征。
Immunol Rev. 2024 Oct;327(1):83-99. doi: 10.1111/imr.13413. Epub 2024 Oct 29.
7
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.基因治疗脑白质营养不良:从临床前动物研究到临床试验。
Neurotherapeutics. 2024 Jul;21(4):e00443. doi: 10.1016/j.neurot.2024.e00443. Epub 2024 Sep 13.
8
A minimally invasive endovascular approach to the cerebellopontine angle cistern enables broad CNS biodistribution of scAAV9-CB-GFP.微创血管内入路小脑脑桥角池可使 scAAV9-CB-GFP 在中枢神经系统内广泛分布。
Mol Ther. 2024 Oct 2;32(10):3346-3355. doi: 10.1016/j.ymthe.2024.08.024. Epub 2024 Aug 26.
9
Neurosurgical gene therapy for central nervous system diseases.神经外科基因治疗中枢神经系统疾病。
Neurotherapeutics. 2024 Jul;21(4):e00434. doi: 10.1016/j.neurot.2024.e00434. Epub 2024 Aug 26.
10
GM1 gangliosidosis type II: Results of a 10-year prospective study.GM1 神经节苷脂贮积症 II 型:一项 10 年前瞻性研究的结果。
Genet Med. 2024 Jul;26(7):101144. doi: 10.1016/j.gim.2024.101144. Epub 2024 Apr 16.